MK-4830
- Generic Name
- MK-4830
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
MK-4830 is a monoclonal antibody that targets the myeloid-specific immunoglobulin-like transcript (ILT) 4 receptor.
- Associated Conditions
- -
- Associated Therapies
- -
Melanoma Clinical Trials 2024: EMA, PDMA, FDA Approvals
DelveInsight's 'Melanoma Pipeline Insight 2024' covers 150+ companies and 170+ pipeline drugs, including IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, and BioNTech SE. Key therapies like Amtagvi (Iovance Biotherapeutics) received FDA fast-track approval in 2024 for metastatic melanoma. Neoadjuvant immunotherapy became standard care for stage III melanoma after ESMO 2024 updates. The report assesses therapies by product type, stage, route of administration, and molecule type, highlighting active and inactive pipeline products.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath